SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

MTEX is trending due to speculation of a potential short squeeze, fueled by its low float and recent price volatility; the community is actively discussing entry points, potential price targets, and comparing it to other stocks that have experienced similar explosive runs; traders are closely monitoring volume and key resistance levels, anticipating a breakout.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending amid a lawsuit against Metsera and Novo Nordisk over a breached merger agreement, sparking debate about competitive pressures in the obesity drug market. The community is discussing Pfizer's legal strategies, potential White House support, and whether it will counter Novo's bid or pursue alternative acquisitions like Viking Therapeutics. Some traders are eyeing LEAPS calls and upcoming earnings, while others express frustration with the stock's price movement.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending as investors discuss its potential in the AI-driven energy sector, drawing comparisons to Bloom Energy's success with natural gas fuel cells. Community members are speculating about upcoming news, contracts, or partnerships that could send the stock parabolic, while also noting the low float could lead to significant price movement.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

GALT is trending as investors anticipate presentations at the AASLD Liver Meeting in November, focusing on Belapectin's potential in treating cirrhosis, especially in combination with GLP-1 drugs. The community is actively discussing potential partnership or buyout news before year-end, along with the possibility of a short squeeze. Discussions center on potential buyout prices and the impact of presentations on the stock's valuation.

Ucore Rare Metals, Inc. Is a technology company, which engages in the business of metal separation products, and services to the mining and mineral extraction industry. Its projects include Bokan-Dotson Ridge Rare Earth Element. The company was founded on October 5, 2006 and is headquartered in Halifax, Canada.

Ucore Rare Metals Inc

Ucore Rare Metals Inc.

$UURAF is trending due to recent Canadian government funding approval for its rare earth processing facility, sparking optimism about the company's growth and its role in reducing reliance on China. The community is buzzing about the potential impact on the stock price and Ucore's strategic partnerships, viewing this as a major milestone in derisking the RapidSX technology. This news reinforces the broader narrative around securing domestic rare earth supply chains, positioning Ucore as a key player in the sector.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending due to increased trading volume and price gains, contrasting with the performance of some of its sector peers. Community discussions revolve around potential catalysts, upcoming presentations, and the stock's recovery following recent events. Some investors are expressing frustration with management and lingering concerns around a prior FDA comment.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB is trending due to recent analyst upgrades and strong Atlas revenue growth, fueling speculation about its potential in the AI space. Community members are actively discussing the stock's breakout potential and debating whether it's overvalued, while also noting insider selling activity. Some are comparing it to other cloud and data stocks like Snowflake and Oracle, citing the broader sector's performance.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as investors anticipate upcoming earnings, with community discussions focused on whether the company can justify its valuation. Some traders are expecting a post-earnings surge, while others remain cautious, citing potential downside risk if results disappoint. Bullish sentiment appears strong, fueled by the company's perceived leadership in AI and recent government contracts.

"Shina Inu is a decentralized meme token on the Ethereum blockchain. Its mission is to give back to the crypto community, give to charity, and win the heart of the greatest token of all time, Shiba Inu!   Shina Token is a very fun meme token project that has sold many rare and beautiful NFTs. NFT sales are used to support the team and provide upcoming features such as exclusive access to events and rewards that will soon be announced."

Shina Inu

Shina Inu is trending as the community highlights the crypto's strong chart structure, increasing bullish momentum, and potential breakout levels being tested. Many believe $SHI is undervalued and in a phase of quiet accumulation by whales, with a 'CBM' event potentially on the horizon. Discussions revolve around the patience of holders and the expectation of a significant move soon.

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Metsera Inc.

Metsera Inc

Metsera (MTSR) is trending due to a potential bidding war between Novo Nordisk and Pfizer to acquire the company, driven by the race to dominate the lucrative obesity drug market. Community discussions revolve around the implications of Pfizer's lawsuit against Metsera and Novo Nordisk, with some speculating about a potential higher bid from Pfizer or an entry from Eli Lilly.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients...

TriSalus Life Sciences to Participate in Upcoming September Investor Conferences

TriSalus Life Sciences Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients...

TriSalus Life Sciences, Inc. (TLSI) Reports Q2 Loss, Tops Revenue Estimates

TriSalus Life Sciences, Inc. (TLSI) delivered earnings and revenue surprises of -22.73% and +5.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates

Myomo (MYO) delivered earnings and revenue surprises of 0.00% and +6.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zimmer Biomet (ZBH) Beats Q2 Earnings and Revenue Estimates

Zimmer (ZBH) delivered earnings and revenue surprises of +4.55% and +1.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates

OrganiGram (OGI) Reports Q2 Loss, Beats Revenue Estimates (Revised)

TriSalus Life Sciences Inc. (TLSI) shares were in the spotlight on Thursday morning after the company’s <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.trisaluslifesci.com/news-releases/news-release-details/trisalus-life-sciences-reports-q4-and-full-year-2024-financial">fourth-quarter</a> loss exceeded Wall Street projections, but revenue topped expectations.TriSalus reported a 44% jump in its fourth-quarter (Q4) revenue to $8.3 million, higher than an analyst estimate of $8.25 million, according to FinChat data.The company’s loss per share narrowed to $0.4, compared to $1.57 in the same quarter a year ago, but it was wider than the estimated loss of $0.32.TriSalus reaffirmed its previous guidance for 2025 and said it expects sales growth of over 50% and its gross margin to exceed 87%, higher than the 86% reported for 2024. &nbsp;The oncology-focused medical technology company also said that it expects to be earnings before interest, tax, depreciation, and amortization (EBITDA) positive this year and achieve positive cash flow by the second half, extending its total cash runaway beyond this year.The company ended 2024 with $8.5 million in cash and cash equivalents.Operating expenses are also expected to reduce over 20% owing to reductions in research and development costs.On Stocktwits, retail sentiment continued to trend in the ‘extremely bearish’ territory while message volume jumped from ‘low’ to ‘high’ over the past 24 hours.<figure class="image"><img style="aspect-ratio:649/151;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_27_at_11_02_29_AM_png_72bc5e484f.webp" alt="TLSI's Sentiment Meter and Message Volume as of 11:30 a.m. ET on March 27, 2025 | Source: Stocktwits" width="649" height="151"><figcaption>TLSI's Sentiment Meter and Message Volume as of 11:30 a.m. ET on March 27, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism about the company’s guidance.<stembedurl>https://stocktwits.com/FE123/message/609391420</stembedurl>Another highlighted the company’s growth in revenue.<stembedurl>https://stocktwits.com/FE123/message/609361644</stembedurl><a href="https://stocktwits.com/symbol/TLSI">TLSI shares</a> gained by over 12% this year but are down by over 40% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/new-fortress-energy-sells-jamaican-assets-to-excelerate-energy/chJ2EtuRbE4">New Fortress Energy Sells Jamaican Assets, Operations To Excelerate Energy For $1.06B: Stock Tumbles But Retail Cheers The Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

TriSalus Life Sciences’ Q4 Loss Exceeds Projections, Revenue Tops Estimates – Retail Stays Pessimistic

The company reaffirmed its previous guidance for 2025 and said it expects sales growth of over 50% and its gross margin to exceed 87%, higher than the 86% reported for 2024. 

Equity

TriSalus Life Sciences Announces Key Appointments to Board of Directors

TriSalus Life Sciences Inc. (Nasdaq: TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with...

TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed

TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company was founded on September 11, 2020, and is headquartered in Westminster, CO.

TriSalus Life Sciences Inc

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

TLSI
TriSalus Life Sciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TLSI News

TLSITriSalus Life Sciences Inc